December 2, 2024 CTAD 2024 Fuels the Momentum in Advancing Alzheimer’s Disease Detection & Treatment with a Spotlight on Blood-Based Biomarkers read more
October 3, 2024 Insights from ECTRIMS 2024: Exploring MS Biomarkers and the Role of Quanterix read more
March 29, 2024 Breaking Ground in Alzheimer’s Diagnosis: Simoa® p-Tau 217 Blood Test Receives FDA Breakthrough Device Designation read more
March 14, 2024 Advancing Alzheimer’s Disease Pathology Detection with Simoa® ALZpath p-Tau217 Assay read more